Drug delivery experts

Screens drug candidates in silico, including SGLT1 and GLUT5 modulators and Fyn kinase inhibitors.

Runs point-cloud protein cavity analysis to predict off-target binding in early toxicity screening.

Develops a macrophage-targeting platform for Gaucher disease and processes for affordable biosimilars.

Develops drug products, including formulations that improve drug retention for local cancer treatment.

Builds cell-based assays for SGLT1 and GLUT5 transporters and bile acid receptors FXR and TGR5.

Maps natural product biosynthesis and builds digital microfluidic screening for drug discovery.

Develops lipid mesophase and lipid nanoparticle systems for controlled release of biologics and drugs.

Develops amino acid-based oral formulations for iron bioavailability and intestinal electrolyte absorption.

Synthesizes heterocyclic small molecules that target p38 kinase docking sites.